Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

• ClinicalTrials.gov Identifier: NCT00649038
• Recruitment Status: Completed
• First Posted: April 1, 2008
• Last Update Posted: April 1, 2008
• Sponsor: Mylan Pharmaceuticals
• Information provided by: Mylan Pharmaceuticals

Study Description

Brief Summary:

The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg; Drug: Lotensin HCT® Tablets 20 mg/25 mg	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Official Title: Single-Dose Food in Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers
• Study Start Date: December 2002
• Actual Primary Completion Date: December 2002
• Actual Study Completion Date: December 2002

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg	Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg; 20/25mg, single dose fed
Active Comparator: 2; Lotensin HCT® Tablets 20 mg/25 mg	Drug: Lotensin HCT® Tablets 20 mg/25 mg; 20/25mg, single dose fed

Outcome Measures

Primary Outcome Measures :

1. Bioequivalence [ Time Frame: within 30 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female.

  1. Women of childbearing potential must have negative serum -human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on Sunday or Monday, serum samples for β-HCG testing may be collected and sent for analysis within 48 hours prior to dosing for both study periods. An additional serum (beta-HCG) pregnancy test will be performed upon completion of the study.

  2. Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. Acceptable forms of contraception include the following:

     1. oral contraceptives initiated at least 3 months prior to the start of the study and continued during the study, or
     2. intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
     3. barrier methods containing or used in conjunction with a spermicidal agent, or
     4. postmenopausal or surgical sterility accompanied with a documented postmenopausal course of at least one year (tubal ligation, oophorectomy or hysterectomy).

  3. During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form.

     3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and all subjects within 15% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).

     4. All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, Hepatitis B, Hepatitis C, and HIV tests, a 12-lead ECG, and urine drug screen including amphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.

     Exclusion Criteria:

• 1. Institutionalized subjects will not be used. 2. Social Habits:

  1. Use of any tobacco products.
  2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
  3. Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.
  4. Any recent, significant change in dietary or exercise habits.
  5. A positive test for any drug included in the urine drug screen. 3. Medications:
  1. Use of any medication within the 14 days prior to the initial dose of study medication, excluding hormonal contraceptives or hormonal replacement therapy initiated at least 3 months prior to study medication dosing.

  2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication, excluding hormonal contraceptives or hormonal replacement therapy initiated at least 3 months prior to study medication dosing.

     4. Diseases:

  1. History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic disease.
  2. History of angioedema
  3. History of drug and/or alcohol abuse.
  4. Acute illness at the time of either the pre-study medical evaluation or dosing.

  5. Positive test for HIV, Hepatitis B, or Hepatitis C.

     5. Abnormal and clinically significant laboratory test results:

  1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).

  2. Abnormal and clinically relevant ECG tracing. 6. Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.

     7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.

     8. Allergy or hypersensitivity to benazepril HCl or hydrochlorothiazide or any other related products.

     9. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.

     10. Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.

Contacts and Locations

Locations

United States, North Dakota

PRACS Institute, Ltd.

Fargo, North Dakota, United States, 58104

Sponsors and Collaborators

Mylan Pharmaceuticals

Investigators

• Principal Investigator: James Carlson, Pharm. D.; PRACS Institute Ltd.

More Information

Additional Information:

Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use  Recalls, Market Withdrawals and Safety Alerts 

• Responsible Party: Will Sullvan, Global Head of Product Risk and Safety Management, Mylan Inc.
• ClinicalTrials.gov Identifier: NCT00649038 History of Changes
• Other Study ID Numbers: BEHZ-0211
• First Posted: April 1, 2008
• Last Update Posted: April 1, 2008
• Last Verified: March 2008

Additional relevant MeSH terms:

Hydrochlorothiazide; Benazepril; Antihypertensive Agents; Diuretics; Natriuretic Agents; Physiological Effects of Drugs; Sodium Chloride Symporter Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Angiotensin-Converting Enzyme Inhibitors; Protease Inhibitors; Enzyme Inhibitors